# Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

> **NCT07439887** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ray Therapeutics, Inc.** · enrollment: 18 (estimated)

## Conditions studied

- Stargardt Disease

## Interventions

- **GENETIC:** RTx-021

## Key facts

- **NCT ID:** NCT07439887
- **Lead sponsor:** Ray Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-28
- **Primary completion:** 2030-12-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07439887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07439887, "Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07439887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*